View metadata, citation and similar papers at core.ac.uk

brought to you by CORE

provided by Institute of Cancer Research Repository

1 **BRITISH JOURNAL CANCER**

2 200 Structured abstract

3 5000 words excluding abstract, ref and legends

4 1 Table and 5 Figures

5 Max 60 References

6 **Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the**
7 **phenotypic effect of *ESR1* mutations**

8

9 Elena Lopez-Knowles[1,2], Alex Pearson[1], Gene Schuster[1,2], Pascal Gellert[1,2], Ricardo Ribas[1],
10 Belinda Yeo[2,3,4], Ros Cutts[1], Richard Buus[1,2], Isaac Garcia-Murillas[1], Ben Haynes[2], Lesley-Ann
11 Martin[1], Ian Smith[3], Nick Turner[1,3], Mitch Dowsett[1,2]

12

13 [1] The Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research,
14 London, UK, [2]Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital,
15 London UK, [3]Breast Unit, Royal Marsden Hospital, London, UK, [4]Olivia Newton-John Cancer
16 Research Institute, Melbourne, Australia

17

18

19 Corresponding Author:
20 Mitch Dowsett
21 Ralph Lauren Centre for Breast Cancer Research
22 Royal Marsden NHS Foundation Trust
23 LONDON, SW3 6JJ, UK
24 Tel: +44 207 808 2887; Fax: +44 207 376 3918
25 E-mail: mitch.dowsett@icr.ac.uk

26

27

Abstract

Background

Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease.

Materials and methods

The mutational landscape of 198 regions in 16 key breast cancer genes and RNA expression of 209 genes covering key pathways was evaluated in paired biopsies before AI treatment and at progression on AI from 48 patients. Validity of findings was assessed in another five ESR1-mutated tumours progressing on AI

Results

Eighty-nine mutations were identified in 41 matched pairs (*PIK3CA* in 27%; *CDH1* in 20%). *ESR1* (n=5), *ERBB2* (n=1) and *MAP2K4* (n=1) had mutations in the secondary sample only. There was very high heterogeneity in gene expression between AI-resistant tumours with few patterns apparent. However, in the *ESR1*-mutated AI-resistant tumours, expression of four classical oestrogen-regulated genes (ERGs) was 7-fold higher than in *ESR1* wild-type tumours, a finding confirmed in the second set of *ESR1*-mutated tumours. In *ESR1* wild-type AI-resistant tumours ERG expression remained suppressed and was uncoupled from the recovery seen in proliferation.

Conclusions

Major genotypic and phenotypic heterogeneity exists between AI resistant disease. ESR1 mutations appear to drive oestrogen-regulated processes in resistant tumours.

Keywords: breast cancer, aromatase inhibitor, ESR1, mutations

52 **Background**

53 Aromatase inhibitors (AIs) are the standard of care as first-line treatment for
54 postmenopausal women with oestrogen receptor positive (ER+) advanced breast cancer
55 (BC)[1]. However, the objective response rate to AIs in the metastatic setting is between 20%-
56 40% and virtually all patients eventually relapse with AI-resistant disease[2,3]. It is critical to
57 understand the molecular drivers of the resistance to allow rational use of subsequent or
58 concurrent therapy. Several potential mechanisms of resistance have been described
59 including changes in the expression of ER or its coregulators, as well as the *ESR1* mutational
60 status. *ESR1* mutations in the ligand-binding domain of ER lead to constitutive activity in
61 model systems[4] and have been detected in 15-20% of patients with metastatic ER+
62 endocrine resistance BC[5-10]; up to 40% of patients have been reported to have *ESR1*
63 mutated circulating tumour (ct) DNA[11]. Other potential mechanisms of resistance to
64 endocrine therapy include the activation of signalling pathways such as the PI3K/mTOR
65 pathway[12].

66 Paired tumour biopsies before and at recurrence or progression on AIs are infrequently
67 available. However, in our previous report of 55 such pairs we found a highly variable
68 immunohistochemical phenotype of several candidate markers between pre-AI and AI-
69 resistant biopsies[13]. Others[14] have reported similar observations that indicate that multiple
70 mechanisms of resistance occur to AI. While loss of ER occurred in some cases, others
71 recurrences showed enhanced expression of ER suggesting persistent ER functioning but
72 downstream markers of such functioning were not measured to confirm or refute this.
73 Other biopsy pairs showed loss of PTEN or HER2 gain, which are consistent with
74 experimental studies of resistance to oestrogen deprivation[15,16].

75 To further investigate the range of molecular changes that are associated with AI-resistance,
76 we analysed the same sample set[13] using a targeted NGS panel to identify somatic mutation
77 in 16 key genes and a Nanostring panel of 209 genes to identify changes in gene expression
78 in major signalling pathways. We found that the majority of mutations in the AI-resistant
79 tumour were shared with their paired pre-AI sample, but almost half of the pairs showed at
80 least one private mutation. *ESR1*, *ERBB2* and *MAP2K4* had mutations in the secondary
81 sample only, while there was no systematic difference between the primary and secondary
82 sample for the other analysed genes. The expression of classically oestrogen-dependent
83 genes that are down-regulated in almost all AI-treated tumours[17] supported a significant
84 phenotypic impact of ESR1 mutations providing further evidence for the likely benefit from
85 some therapeutic interventions.

86 **Materials and Methods**

87 **Patient selection and characteristics**

88 Samples used in this study have been described previously[13]. In brief, 55 ER+ breast cancer
89 patients from The Royal Marsden Hospital were retrospectively selected if they had
90 relapsed or progressed during AI treatment in the locally advanced or metastatic setting
91 (Discovery cohort, Figure 1). Patient characteristics and clinical management are
92 summarised in Table 1. 37/48 (77%) of patients received endocrine therapy prior to
93 treatment with an AI, with 31/48 (65%) receiving tamoxifen. 5/48 (10%) patients received
94 both tamoxifen and an AI. Paired tissue blocks, pre and post AI treatment, from 48 patients
95 were available for DNA and RNA extraction. Of these 48 patients, a total of 21 patients
96 received tamoxifen prior to the pre AI sample being collected.

To assess the validity of observations made in the discovery cohort on the phenotype of tumours with *ESR1* mutations, a set of biopsies from 5 patients with recurrent disease already known to have *ESR1* mutations post AI treatment was obtained from the ABC-BIO study (Validation cohort, Figure 1). The ABC-BIO study recruits patients at the Royal Marsden Hospital with advanced breast cancer with accessible metastatic deposits for DNA sequencing using the Breast NGS v1.1 probe set including probes to capture ESR1. Biopsies from three other patients in the ABC-BIO study that were known to harbour *ESR1* mutations but had ceased AI treatment for at least 4 weeks prior to biopsy were excluded because of the potential impact on gene expression.

Essential details of molecular analysis are stated below and fully detailed in the supplementary materials.

DNA and RNA extraction

Patients had an FFPE tumour biopsy pre- and post-AI treatment. Tissue sections were microdissected and DNA and RNA were co-extracted using the AllPrep DNA/RNA FFPE Kit (Qiagen, Hilden, Germany), with an extended overnight digestion for the DNA extraction being the only modification from the manufacturer's instructions. Quantification was done using high sensitivity RNA and DNA Qubit assays (Thermo Fisher Scientific, Carlsbad, CA) and on a Bio-Rad QX200 droplet digital PCR (ddPCR) using RNAseP (Thermo Fisher Scientific) [11]. Samples from the validation cohort were also extracted following the same protocol; however, only one of five cases had a pre-AI treatment block available.

Ion PGM sequencing

DNA from the discovery cohort was amplified using a custom panel targeting 198 regions within 16 genes. These genes represent the most mutated genes in breast cancer. Five

120 genes (*CDH1*, *GATA3*, *MAP2K4, MAP3K1*, *PTEN*) were covered between 73 and 100%, while
121 for the other 11 genes (*AKT1*, *BRAF*, *ERBB2, ESR1*, *KIT*, *KRAS*, *PIK3CA*, *PIK3R1*, *RUNX1, SF3B1*,
122 *TP53*), amplicons for known hotspot regions were designed, resulting in a 100% coverage,
123 except for *ERBB2* (90%) and *RUNX1* (5%). Libraries were prepared with 10ng of DNA and
124 sequenced to a median depth of 782X using the Ion Ampliseq Library Kit v2.0 (Thermo Fisher
125 Scientific).

126 **MiSeq and NextSeq sequencing**

127 DNA from 5 tumours from the discovery cohort that were unsuccessful with Ion Torrent and
128 8 from the validation cohort were run on the Miseq or NextSeq (Illumina, San Diego, CA)
129 using the Breast NGS v1.1 probe set. Protocol and analysis details are described in
130 supplementary materials. For the purposes of this report only *ESR1* mutational data was
131 extracted.

132 **Mutational validation**

133 Selected *ESR1*, *TP53*, *HER2*, *MAP2K4*, *MAP3K1* and *PIK3CA* mutations were validated by
134 droplet digital PCR (ddPCR) on a QX200 ddPCR system (Bio-Rad, Hercules, CA), with primers
135 (900nM) and probes (250nM) and annealing temperatures described in Table S1. Cycling
136 conditions and calculation of mutant concentration were described previously[11,18].
137 *PIK3CA* C420R and E418K and *GATA3* K358fs mutations were validated by cycle sequencing.

138 **Nanostring gene expression analysis**

139 RNA was run on a NanoString nCounter™ with 2 custom gene expression panels that
140 comprised of 194 genes in CodeSet 1 and 70 genes in CodeSet 2, according to
141 manufacturer's guidelines. These were comprised of reference genes, the PAM50 gene set
142 and genes involved in steroid hormone synthesis, ER targets, receptor tyrosine kinases, cell

143 cycle/proliferation, apoptosis, cell signalling, mTOR and APOBEC (Table S2A and S2B).
144 Intrinsic subtypes were identified by NanoString Technologies using a proprietary algorithm.
145 NanoString was performed for39 pairs and 2 post-AI samples from the discovery cohort and
146 1 pair and 2 post-AI from the validation cohort.

147 **Statistical Analysis**

148 Statistical tests were performed as indicated using either R v3.2.3 or Graphpad Prism v7. P
149 value <0.05 was considered statistically significant. Were appropriate paired analyses were
150 performed.

151 **Results**

152 **Discovery Cohort**

153 **Population**

154 A consort diagram showing the sample availability in the population is provided in Figure 1.
155 The clinicopathological characteristics of the 48 sample pairs with adequate either DNA
156 and/or RNA data are shown in Table 1. In summary, the first tissue sample (pre-AI) was
157 taken most frequently (62%) from the primary BC or from a local recurrence (35%). At the
158 time of this sample, 50% of patients had early disease, 42% had loco regional relapsed
159 disease and 8% had metastatic BC. The second, post-AI tissue was most frequently (54%)
160 from a site of local recurrence. At the time of the post-AI tissue, 58% of patients had
161 metastatic disease, 36% had loco regional recurrence and for 6% of patients the post-AI
162 tissue represented progression in the primary after neoadjuvant AI.

163 **IonTorrent mutational landscape**

164 Using stringent criteria (see supplementary material), we identified a total of 89 somatic
165 mutations (47 unique genomic positions) among the 41 pairs of sample with adequate DNA
166 and that passed QC, Table S3). The mutations are shown for individual patients in Figure 2
167 along with data on PAM50 subtype and previously reported IHC status for ER, PgR, PTEN,
168 Ki67 and HER2 (FISH as necessary). Across all samples, 36 mutations were found in both the
169 primary and secondary samples (shared mutations) whilst 18 mutations were private to one
170 sample of the pair (Figure S1). For the mutations that were identified in both paired
171 samples, there was no significant difference in variant allele frequency (VAF) between the
172 samples (data not shown). For many pairs we found at least one mutation with high VAF in
173 both samples suggesting a common founding clone. There was no significant difference
174 between the total number of mutations identified on the pre and post samples. The most
175 frequently mutated gene was *PIK3CA* (27%) followed by *CDH1* (20%). Three genes: *ERBB2*
176 (L755S), *MAP2K4* (located at Intron 9-10) and *ESR1* (D538G and E380Q) were mutated
177 exclusively in the post sample and were exclusive of each other. Mutations were validated
178 by ddPCR and cycle sequencing (Table S4) with identified VAFs similar to those found by
179 sequencing, demonstrating high reproducibility of the data. Of the 12 sample pairs with no
180 mutations detected, three were HER2 positive and four had a marked decrease of ER
181 staining in the post-AI sample. Both of these phenotypes might lead to less selective
182 pressure for the acquisition of mutations.

183 ***ESR1* mutations**

184 To complement the *ESR1* mutational analysis five further samples from the discovery cohort
185 that were unsuccessful with Ion Torrent were run with an NGS Breast v1.1 panel

186 (Supplementary materials). This identified one additional *ESR1* mutation in a post-AI sample.
187 This mutation was a previously unreported substitution followed by an insertion at the
188 aa536 hot-spot of known mutations (**L536indelGV**). In all of the five patients with *ESR1*
189 mutations the resistant biopsy was in the metastatic setting (Figure S2). In one of these
190 cases (patient 23) an intermediate sample taken after 5 years of tamoxifen in the metastatic
191 setting and before AI treatment was available and was found to be *ESR1* wild type.

192 **Gene Expression**

193 For five genes both IHC and gene expression data (Table S5) were available and for all of
194 these there was a strong significant correlation between the 2 measurements (Table S6)[19].
195 Two-way hierarchical clustering of the global gene expression in the pre- and post-AI groups
196 showed 38% (15/39) of pairs clustered together (Figure 3A). Thirty-six pairs (plus two pre-
197 and two post-AI samples) had PAM50 subtype calculated (Table S7). Only 56% of sample
198 pairs maintained their PAM50 subtype at progression after AI treatment (Table S8). Of
199 particular note only one case was classified as basal-like at baseline but six were classified as
200 basal-like at resistance. Low expression of oestrogen response genes were a consistent
201 feature of this group. The clustering shows some distinct patterns with three major
202 branches labelled A, B and C in Figure 3A. Branch A consists largely of luminal A and luminal
203 B samples with substantial heterogeneity between them. Branch B consists mainly of HER2-
204 enriched samples and some luminal B. In contrast branch C contains all of the basal-like
205 samples, most of which were unpaired post-treatment samples. The proliferation group of
206 genes appeared to be the dominant feature in clustering the samples most notably into 2
207 sub-clusters of branch C.

208 Figure 3B shows 2-way hierarchical clustering of just the AI-resistant samples. While 4 main
209 clusters can be recognised, the very wide heterogeneity in gene expression in these samples
210 is evident with few groupings due to consistent patterns of expression across the gene set. A
211 small group of tumours with basal-like features (branch A) again segregated from the others
212 based mainly on low expression of oestrogen-regulated genes and high expression of genes
213 in the immune cluster. The central 2 clusters (B and C) in Figure 3B differ from the others
214 mainly by their higher expression of oestrogen-regulated genes and contain the ESR1
215 mutated tumours (see below). The segregation of clusters B and C from one another is then
216 related mainly to proliferation-associated genes. Notably, those with the relatively high
217 proliferation were associated with relatively high signal transduction and immune signalling.
218 The segregation of the cluster classified as HER2-enriched was unexpectedly not dependent
219 on high levels of genes associated with signal transduction but rather on either relatively
220 high proliferation or relatively low expression of immune-related genes.
221 Eighteen genes were significantly (FDR 5%) downregulated and one (TBP) was upregulated
222 at progression after AI (Figure 4). Ten of the 13 most markedly down-regulated were known
223 to be subject to regulation by oestrogen signalling. After exclusion of ER negative samples
224 13/18 genes were significantly differentially expressed. The five genes no longer significantly
225 different were *TFF3, SCUBE2, SLC39A6, TBP, PIK3R2* and *GATA3*. This indicates that
226 suppression of a major axis of oestrogen regulation is maintained despite these tumours
227 demonstrating clinical resistance to AI. Further, expression of *ESR1* and ERa show a strong
228 correlation with the significantly differentially expressed genes (Figure S3A). The discovery
229 cohort is phenotypically heterogeneous, yet unsupervised clustering of the 18 differentially
230 expressed genes reveals robust downregulation of ERGs in the majority of tumours (Figure
231 S3B).

232 Twenty-one patients with paired samples, of which 16 have expression data, had received
233 tamoxifen prior to the pre-AI sample being collected and conceivably this could have
234 impacted on the expression of these 18 differentially regulated genes in the pre-AI sample.
235 However there was no significant difference in gene expression for any of the genes
236 according to prior tamoxifen treatment (Figure S4). This lack of effect of prior tamoxifen
237 may be due to the drug's partial agonist activity which is marked in postmenopausal
238 women[20].

239 **ESR1 Mutation and Gene Expression**

240 There was no significant difference in expression of four oestrogen-regulated genes (TFF1,
241 GREB1, PDZK1 and PgR) that we have previously used as markers of oestrogenic signalling[17],
242 in the pre-AI samples from the 5 patients in the discovery cohort that went on to acquire an
243 *ESR1* mutation compared with those that did not (Figure S5). In four of the five cases it was
244 notable however that oestrogen regulated gene expression was is in the upper range of that
245 in all samples. Expression of the four oestrogen-regulated genes in post-AI samples with
246 *ESR1* mutations was on average more than 2-fold higher than in *ESR1* wildtype samples for
247 individual genes, and the average expression of these genes in post-AI samples with *ESR1*
248 mutations was more than 6-fold higher than in post-AI samples with wildtype *ESR1* (Mann
249 Whitney P=0.006, Figure S5).

250 We used the validation cohort to assess the consistency of these observations of a
251 relationship between oestrogen-regulated gene expression and *ESR1* mutations. This cohort
252 consisted of an additional five metastatic samples with previously described *ESR1* mutation
253 in a sample taken after AI treatment increasing the number of *ESR1* mutated cases with
254 gene expression data to 10. The clinicopathological characteristics of the samples (1 pair and

255 4 Post-AI samples) are shown in Table S9 and the treatment chronology from diagnosis to
256 death is shown in Figure S6.
257 Gene expression of 33 genes was significantly different in the progression sample between
258 *ESR1* wild-type and the 10 mutated tumours (Figure S7). FOXO3a was the only gene
259 observed to have lower expression in *ESR1* mutant post-AI samples. Using Fisher's exact
260 test, the remaining 32 genes with higher expression in *ESR1* mutant post-AI samples were
261 significantly enriched for annotations associated with proliferation and most markedly with
262 oestrogen regulation. Five of the genes are part of the 11-gene proliferation signature in
263 PAM50[21](p = 0.02, fisher exact test), and 11 are oestrogen-regulated (GSEA Molecular
264 Signature Database Hallmark of Estrogen Response Early/Late[22], p = 0.01, fisher exact test).
265 In addition, two of these genes (MELK and BIRC5) are associated with worse outcome or
266 metastasis[23,24]. After exclusion of ER negative samples, 25/33 genes were significantly
267 differentially expressed, including 8/10 ERGs and the 5 genes from the PAM50 proliferation
268 signature. The eight genes no longer significantly different were *IL6ST, PGR, FOXO3A, FKBP4,*
269 *HRAS, KIF2C, CXXC5* and *RPLP0.*
270 Figure 5A shows the associations between oestrogen regulated gene (ERG) expression and
271 *ESR1* mutational status between all 10 ESR1 mutated cases and the non-mutated cases
272 according to baseline or post-treatment status. Post-AI samples with *ESR1* mutations had
273 more than 7-fold higher ERG expression than post-AI wild-type samples (Mann Whitney P=
274 1.7e-6). Figure 5B shows no significant differences in the PAM50 proliferation genes
275 between the post treatment samples according to *ESR1* mutation status. A linear scale plot
276 emphasizes the magnitude of the difference in ERG expression between post-AI samples
277 with or without *ESR1* mutation (Figure S8) and the separation in the samples according to
278 ERG expression is particularly clear when shown in a waterfall plot (Figure 5C). It is notable

279 that the post-AI *ESR1*-mutated tumour with the lowest oestrogen regulated expression
280 carried an E380Q mutation and was also HER2-positive though this is the only ESR1 mutated
281 sample with HER2 overexpression making the importance of its association with low ERG
282 expression uncertain.
283

284 **Discussion**

285 Several thousand women diagnosed with ER+ breast cancer recur each year with endocrine
286 resistant disease. The majority are postmenopausal and almost all will have received an AI
287 before or after their recurrence and will require management of their AI-resistant disease.
288 Many potential mechanisms have been reported in model systems but few of these have
289 been confirmed as being associated with AI-resistance in the clinic. To a large degree this is
290 because tissues are difficult to acquire in which to study such associations. The collection of
291 paired pre-AI and AI-resistant tissues assessed here for mutational status and expression
292 levels of BC associated genes although modest in size is therefore an uncommon cohort.
293 Our earlier report revealed very marked heterogeneity between resistant tumours in key
294 IHC biomarkers[12]. Of note, ER expression was maintained or enhanced in the majority of
295 tumours and was felt to be consistent with a potential for oestrogen signalling in the face of
296 AI to be a driver of resistance, a mechanism that is supported in only a minority of ER+
297 resistant tumours in the current study.

298 Our data support those from more wide-ranging studies of metastatic breast cancer, in that
299 there was an absence of observed major increases in the acquisition of driver mutations in
300 metastases[10,25,26] at least among the selected panel of frequently-mutated genes assessed.
301 The only gene that differed substantially was *ESR1* in which mutations have been described

302 to be markedly enriched in metastases after AI-treatment[5,7-10]. In this study we identified
303 *ESR1* mutations in 11% of patients, which is at lower end of the reported frequency. This
304 may be due to many of our samples being local recurrences.

305 *ESR1* mutated recurrent breast cancer has become a focus of attention in the possible
306 development of new agents, such as selective oestrogen receptor degraders but very little
307 has been reported on the phenotype of the *ESR1*-mutated tumours. Evidence from model
308 systems indicates the ligand-independent activity of the hot-spot *ESR1* mutations[4,27-29]. Our
309 clinical data on the significantly higher expression of ERGs when *ESR1* mutations were
310 present, despite the on-going treatment with AI, supports this supports this being valid in
311 clinical tissues. While our observation was made on a relatively small number of samples, it
312 was validated by examination of another cohort from an on-going study of the clinical
313 importance of mutations in metastatic breast cancer. The co-association of the high ERG
314 expression and high proliferation genes in the ESR1 mutated tumours is consistent with the
315 tumour progression being at least partly driven by the mutations. In contrast, the continued
316 suppression of the ERG expression in tumours in which mutations were not detected implies
317 a disconnect between proliferation and oestrogen signalling. Persistent suppression of ERG
318 expression is clearly not a signal for continued anti-tumour effectiveness of the AI:
319 assessment of these genes as a pharmacodynamics marker in this instance would likely be
320 misleading.
321 We observed small numbers of other mutations that could underpin resistance in individual
322 patients. These included a *MAP2K4* mutation which likely disrupts splicing and potentially
323 leads to not recognising exon 9 by the spliceosome or retaining the intron downstream of
324 exon 9 and the *ERBB2* L755S which has been previously associated with lapatinib

325 resistance[30] but has also been associated with response to the alternative HER2 tyrosine
326 kinase inhibitor, neratinib[31].

327 *PIK3CA* and *TP53* are the most commonly mutated genes in BC with over 30% of patients
328 carrying mutations in either of these genes (IntOgen database[32]). In our study we found that
329 27% of the patients had mutations in one or both of their samples in *PIK3CA*, but only 15%
330 had a *TP53* mutation (likely due to targeting of *TP53* hotspots in our targeted panel). We
331 also found many patients with a *CDH1* mutation (20%). Loss of CDH1 is a common feature of
332 lobular breast cancer which is almost always ER+. *CDH1* controls the cellular adhesion
333 dynamics[33] and its loss has been associated with increased cancer invasion[34]. These features
334 might explain the unusually high frequency in this selection of patients, all of whom
335 relapsed after AI treatment.

336 There was little consistency other than marked down-regulation of ERGs in most patients in
337 recurrent samples. PAM50 subtypes were maintained in >55% of patients in agreement with
338 the 61% recently described in matched primary and metastatic pairs[5]. The meaning of the
339 intrinsic subtypes in metastatic disease is however unclear particularly when, as in this
340 study, transcriptional features that underpin the subtyping are impacted by medical
341 therapy.

342 The most notable feature of the gene expression analyses was the very high degree of
343 heterogeneity between recurrent tumours; this was apparent even within the three or four
344 main clusters identified. This does not necessarily imply that gene expression profiling of
345 recurrent tumours is without value. Rather it supports the need for individualised
346 interpretation of profiles for individual tumours. This is especially so with regard to features
347 such as oestrogen regulation, that might imply the likely benefit or not of alternative

348 targeting of oestrogen signalling, or individual signal transduction pathways that align with
349 particular inhibitors.
350 Some weaknesses in the current study need to be considered. Many patients had received
351 chemotherapy or tamoxifen prior to the pre-AI sample and then progressed after being
352 treated with an AI. Although prior treatment with tamoxifen might have been expected to
353 impact on gene expression, particularly of known oestrogen-regulated genes, our analyses
354 revealed no significant effect of this prior treatment on the main gene changes noted. Our
355 mutational and transcriptional characterisation was based around features known to be of
356 relevance in breast cancer. An assessment at a more genome-wide level would require a
357 much larger sample set to have confidence in novel observations.

358 In summary, there is major inter-tumour heterogeneity of genotypic and phenotypic
359 features that may drive resistance to AIs in recurrent breast cancer, requiring highly
360 individualised interpretation of likely dominant pathways in particular cases. Mutational
361 analysis of recurrent disease is of value in identifying targetable abnormalities. Mutations in
362 ESR1 gene are frequently acquired in recurrent disease, having enhanced ERG expression
363 alongside high proliferation-associated genes provides a strong rationale for their targeting
364 with novel agents targeted at the degradation of ligand-independent ER.

365 **Additional information**

366 **Ethics approval and consent**

367 Statement on ethics committee and reference number. Study was performed in accordance
368 with the Declaration of Helsinki.

369 **Availability of data and material**

Publicly archived dataset?

Conflict of interest

No conflicts of interest to disclose

Funding

This work was supported by Breast Cancer Now, working in partnership with Walk the Walk; and the National Institute of Health Research Royal Marsden/Institute of Cancer Research Biomedical Research Centre.

Authors contributions

ELK and AP performed experiments and wrote the manuscript, GS and PG Analyzed the data, RR performed IoT experiment, BY helped with study demographics, RC analysed IoT data, RB and BH helped with NanoString, IGM helped with ddPCR, LAM, IS, NT helped write the manuscript, MD designed study and wrote the manuscript.

Acknowledgements

We would like to thank Monica Arnedos for putting together this sample group and Maria Afentakis and Margaret Hills for performing the IHC analysis.

Supplementary information is available at the British Journal of Cancer's website.

Supplementary materials: in depth description of the materials and methods used in the manuscript.

References

1. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M, Group EGW. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; **21 Suppl 5**: v15-19; doi 10.1093/annonc/mdq160.
2. Johnston SR. New strategies in estrogen receptor-positive breast cancer. *Clin Cancer Res* 2010; **16**(7): 1979-1987; doi 10.1158/1078-0432.CCR-09-1823.

394 3. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR *et al.* Combination
395 anastrozole and fulvestrant in metastatic breast cancer. *The New England journal of*
396 *medicine* 2012; **367**(5): 435-444; doi 10.1056/NEJMoa1201622.
397 4. Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T *et al.* Discovery of naturally
398 occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. *Nat*
399 *Commun* 2017; **8**(1): 1865; doi 10.1038/s41467-017-01864-y.
400 5. Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, O'Brien C *et al.* Somatic mutation, copy number
401 and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive
402 breast cancers. *Ann Oncol* 2016; **27**(10): 1860-1866; doi 10.1093/annonc/mdw286.
403 6. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations-a mechanism
404 for acquired endocrine resistance in breast cancer. *Nat Rev Clin Oncol* 2015; **12**(10): 573-
405 583; doi 10.1038/nrclinonc.2015.117.
406 7. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM
407 *et al.* Emergence of constitutively active estrogen receptor-alpha mutations in pretreated
408 advanced estrogen receptor-positive breast cancer. *Clin Cancer Res* 2014; **20**(7): 1757-1767;
409 doi 10.1158/1078-0432.CCR-13-2332.
410 8. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X *et al.* Activating ESR1 mutations in
411 hormone-resistant metastatic breast cancer. *Nat Genet* 2013; **45**(12): 1446-1451; doi
412 10.1038/ng.2823.
413 9. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M *et al.* ESR1 ligand-binding domain mutations
414 in hormone-resistant breast cancer. *Nat Genet* 2013; **45**(12): 1439-1445; doi
415 10.1038/ng.2822.
416 10. Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I *et al.* Genomic
417 Evolution of Breast Cancer Metastasis and Relapse. *Cancer Cell* 2017; **32**(2): 169-184 e167;
418 doi 10.1016/j.ccell.2017.07.005.
419 11. Schiavon G, Hrebien S, Garcia-Murillas I, Pearson A, Tarazona N, Lopez-Knowles E *et al.* ESR1
420 mutations evolve during the treatment of metastatic breast cancer, and detection in ctDNA
421 predicts sensitivity to subsequent hormone therapy. Paper presented at: American
422 Association for Cancer Research; Pennsylvania Convention Center.
423 12. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance
424 in breast cancer. *J Clin Oncol* 2011; **29**(33): 4452-4461; doi 10.1200/JCO.2010.34.4879.
425 13. Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J *et al.* Biomarker changes
426 associated with the development of resistance to aromatase inhibitors (AIs) in estrogen
427 receptor-positive breast cancer. *Ann Oncol* 2014; **25**(3): 605-610; doi
428 10.1093/annonc/mdt575.
429 14. Criscitiello C, Andre F, Thompson AM, De Laurentiis M, Esposito A, Gelao L *et al.* Biopsy
430 confirmation of metastatic sites in breast cancer patients: clinical impact and future
431 perspectives. *Breast Cancer Res* 2014; **16**(2): 205.
432 15. Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S *et al.* Overcoming endocrine
433 resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-
434 targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein
435 kinase kinase. *Breast Cancer Res* 2014; **16**(5): 430; doi 10.1186/s13058-014-0430-x.
436 16. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK *et al.* Mechanisms of
437 tumor regression and resistance to estrogen deprivation and fulvestrant in a model of
438 estrogen receptor-positive, HER-2/neu-positive breast cancer. *Cancer Res* 2006; **66**(16):
439 8266-8273; doi 10.1158/0008-5472.CAN-05-4045.
440 17. Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P *et al.* Molecular profiling of
441 aromatase inhibitor-treated post-menopausal breast tumors identifies immune-related
442 correlates of resistance. *Clin Cancer Res* 2013; e-pub ahead of print 2013/03/16; doi
443 10.1158/1078-0432.CCR-12-1000.

444 18. Lopez-Knowles E, Segal CV, Gao Q, Garcia-Murillas I, Turner NC, Smith I *et al.* Relationship of
445 PIK3CA mutation and pathway activity with antiproliferative response to aromatase
446 inhibition. *Breast Cancer Res* 2014; **16**(3): R68; doi 10.1186/bcr3683.
447 19. Martin M, Prat A, Rodriguez-Lescure A, Caballero R, Ebbert MT, Munarriz B *et al.* PAM50
448 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. *Breast Cancer*
449 *Res Treat* 2013; **138**(2): 457-466; doi 10.1007/s10549-013-2416-2.
450 20. Dowsett M, Howell A. Breast cancer: aromatase inhibitors take on tamoxifen. *Nature*
451 *medicine* 2002; **8**(12): 1341-1344; doi 10.1038/nm1202-1341.
452 21. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T *et al.* A comparison of PAM50
453 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-
454 treated estrogen receptor-positive breast cancer. *Clin Cancer Res* 2010; **16**(21): 5222-5232;
455 doi 10.1158/1078-0432.CCR-10-1282.
456 22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA *et al.* Gene set
457 enrichment analysis: a knowledge-based approach for interpreting genome-wide expression
458 profiles. *Proc Natl Acad Sci U S A* 2005; **102**(43): 15545-15550; doi
459 10.1073/pnas.0506580102.
460 23. Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretiere JM *et al.* BIRC5
461 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to
462 neoadjuvant chemotherapy. *Breast Cancer Res Treat* 2016; **159**(3): 499-511; doi
463 10.1007/s10549-016-3961-2.
464 24. Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K *et al.* Maternal Embryonic
465 Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in
466 Human Breast Cancer. *Clin Cancer Res* 2016; **22**(23): 5864-5875; doi 10.1158/1078-
467 0432.CCR-15-2711.
468 25. Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL *et al.* Integrated RNA and DNA
469 sequencing reveals early drivers of metastatic breast cancer. *J Clin Invest* 2018; **128**(4): 1371-
470 1383; doi 10.1172/JCI96153.
471 26. Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A *et al.* The genomic
472 landscape and evolution of endometrial carcinoma progression and abdominopelvic
473 metastasis. *Nat Genet* 2016; **48**(8): 848-855; doi 10.1038/ng.3602.
474 27. Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L *et al.* Mutation site and context
475 dependent effects of ESR1 mutation in genome-edited breast cancer cell models. *Breast*
476 *Cancer Res* 2017; **19**(1): 60; doi 10.1186/s13058-017-0851-4.
477 28. Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ *et al.* Estrogen
478 receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine
479 resistance by stabilizing the activating function-2 binding conformation. *Elife* 2016; **5**; doi
480 10.7554/eLife.12792.
481 29. Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF *et al.* Genomic
482 modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic
483 approaches for metastatic breast cancer. *Oncogene* 2017; **36**(16): 2286-2296; doi
484 10.1038/onc.2016.382.
485 30. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC *et al.* Activating HER2
486 mutations in HER2 gene amplification negative breast cancer. *Cancer Discov* 2013; **3**(2): 224-
487 237; doi 10.1158/2159-8290.CD-12-0349.
488 31. Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ. HER2-Mutated Breast Cancer Responds
489 to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase
490 Inhibitor. *J Natl Compr Canc Netw* 2015; **13**(9): 1061-1064.
491 32. Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Tamborero D, Schroeder MP, Jene-Sanz A *et*
492 *al.* IntOGen-mutations identifies cancer drivers across tumor types. *Nat Methods* 2013;
493 **10**(11): 1081-1082; doi 10.1038/nmeth.2642.

494 33. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction
495 promote tumor progression? *Oncogene* 2008; **27**(55): 6920-6929; doi
496 10.1038/onc.2008.343.
497 34. Stafford LJ, Vaidya KS, Welch DR. Metastasis suppressors genes in cancer. *Int J Biochem Cell*
498 *Biol* 2008; **40**(5): 874-891; doi 10.1016/j.biocel.2007.12.016.
499

500 **Figure Legends**

501 Figure 1: Consort Diagram of the 55 AI paired samples (discovery cohort, left) and 5 ESR1
502 mutant samples from the ABCBIO study.

503 Figure 2: Mutation matrix. All somatic mutations in the coding sequence (CDS) are shown
504 together with IHC expression, clinicopathological parameters and PAM50 subtypes. 1 and 2
505 indicate the number of mutations identified.

506 Figure 3: A) Hierarchical clustering of the 39 sample pairs and two unpaired post samples by
507 gene expression. *ESR1* mutational status, pair pre- and post-AI status (together with pair
508 clustering) and PAM50 subtypes are indicated at the top of the cluster. Five gene (row)
509 clusters are annotated by most significant terms generated from compute overlaps analysis
510 in Broad Institute GSEA website
511 (http://software.broadinstitute.org/gsea/msigdb/annotate.jsp). B) Hierarchical clustering of
512 the 41 post samples by gene expression. *ESR1* mutational status and PAM50 subtypes are
513 indicated at the top of the cluster. Five gene (row) clusters were taken from clustering used
514 in Figure 2.

515 Figure 4: A) Arrow plot of 18 genes that changed significantly pre- and post-AI. Red arrows
516 identify increase of expression in the paired post sample and blue arrows a decrease in
517 expression. FDR values for Student's t-test are shown. B) Box plots of the same 18 genes
518 with mean and 95% confidence interval of log2 difference between paired pre and post
519 samples. Genes coloured in black are ERG genes.

520 Figure 5: A) *ESR1* mutations and avERG expression. Box plots of the average expression of
521 TFF1, GREB1, PgR and PDZK1 are shown in the Pre- and Post-AI samples in *ESR1* WT and 13
522 MUT samples (5 from AI study and 8 from additional cohort). B) *ESR1* mutations and PAM50
523 proliferation gene expression. Box plots of the average expression of the PAM50

524 proliferation genes are shown in the Pre- and Post-AI samples. C) Waterfall plot of *ESR1*
525 mutational status and ERG expression. The Dashed line represents the mean of all Pre
526 samples. *Indicates a Post-AI *ESR1* mutant sample that is HER2 positive.
527

528 **Table 1:** Patient demographics. The clinical characteristics of 48 patients with mutational
529 and/or gene expression data.

Clinical characteristics			**n (%)**
Diagnosis	**Age (years)**	Mean	54
		Range	27-86
	Disease status	EBC	41 (85)
		Locally advanced	5 (10)
		Metastatic	2 (5)
Age at start of AI treatment (years)		Mean	62
		Range	33-88
Pre-AI biopsy	**Site**	Primary	30 (62)
		Local recurrence	17 (35)
		Distant recurrence	1 (2)
	Disease Status	EBC	24 (50)
		Locoregional recurrence	20 (42)
		MBC	4 (8)
AI therapy b/w 1st and 2nd biopsy	**Type**	Letrozole	25 (52)
		Anastrozole	21 (44)
		Exemestane	2 (5)
	Disease setting for AI therapy	Adj/neoadj	9 (19)
		Local recurrence	25 (52)
		Metastatic	14 (30)
Post-AI biopsy	**Site**	Primary	7 (15)
		Local recurrence	26 (54)
		Distant recurrence	15 (31)
	Disease Status	EBC	3 (6)
		Locoregional recurrence	17 (36)
		MBC	28 (58)
Endocrine therapy prior AI treatment		None	11 (23)
		Tamoxifen	31 (65)
		Tamoxifen + AI	5 (10)
		Grosrelin	1 (2)
Endocrine therapy after PD on AI		AI	31 (65)
		Tamoxifen	7 (15)
		Fulvestrant	5 (10)
HER2 status of either tissues		HER2 positive[§]	7 (15)
		Trastuzumab received	6 (13)
Overall survival[$] (years)		Median	8.75
		Range	2-33

530 EBC, early breast cancer; MBC, metastatic breast cancer; AI, aromatase inhibitor; PD, progressive disease;
531 §either 1st or 2nd tissue sample; $defined as time from first breast cancer diagnosis to death (alive patients
532 censored)
533

Supplementary Figure and Table Legends

Figure S1: Scatter plot showing the VAFs of mutations per sample pair.

Figure S2: Treatment history of the 5 patients from discovery cohort with *ESR1* mutation. The therapy timeline from pre-AI tissue to deceased status are shown for the 5 patients with *ESR1* mutations.

Figure S3: A) Spearman correlation of 18 significant differentially expressed between Pre and Post samples, ESR1 mRNA expression (Pre, Post and Post – Pre) and ER IHC (Pre, Post and Post – Pre). From 39 paired samples and colored by spearman rho values, *<0.05, **<0.01 and ***<0.001. Red gene expression, black IHC. B) Unsupervised clustering of 18 significant differentially expressed genes (Log2 Post-Pre) and sample pairs with ERa and HER2 expression by IHC.

Figure S4: Effect of prior tamoxifen treatment on 18 significantly differentially expressed genes. Box plots with mean and 95% confidence interval of log2 difference between paired pre and post samples. Top panel, pairs with prior tamoxifen treatment (n=16) and bottom panel pairs without prior tamoxifen treatment (n=23). Genes coloured in black are ERG genes.

Figure S5: Box plots of the average expression of TFF1, GREB1, PgR and PDZK1 are shown in the Pre- and Post-AI samples in *ESR1* WT and five MUT samples from the AI study.

Figure S6: Treatment history of the 5 patients with *ESR1* mutations from the validation cohort. The therapy timeline represents from diagnosis to deceased status.

Figure S7: *ESR1* mutational status and gene expression. Thirty three genes whose expression is significantly associated to *ESR1* mutational status. Purple coloured labels are ERGs and Red coloured labels are part of the PAM50 11-gene proliferation signature.

557 Figure S8: Linear scale plot of avERG expression and *ESR1* mutational status. Green “x”
558 identify Post-AI unpaired samples.
559
560 Table S1. Primers used for sequencing.
561 Table S2. Two gene panels selected for NanoString.
562 Table S3. All mutations identified in the Ion Torrent analysis and their variant allele
563 frequencies.
564 Table S4. ddPCR and sequencing validation results.
565 Table S5. Nanostring normalised log2 expression data
566 Table S6. Correlation between Immunohistochemistry and Nanostring data.
567 Table S7. PAM50 data calls for each sample.
568 Table S8. PAM50 pre- and post-AI contingency table
569 Table S9. Demographics of 8 ABC-BIO samples